SpringWorks Therapeutics, Inc. (NASDAQ:SWTX) Q1 2024 Earnings Call Transcript May 5, 2024 SpringWorks Therapeutics, Inc. isn’t one of the 30 most popular stocks among hedge funds at the end of the third quarter (see the details here). Operator: Good morning. My name is Tawanda, and I will be your conference operator today. At this time, I […]
– Achieved $21.0 million in OGSIVEO® net product revenue in the first quarter – – Received validation from the EMA for MAA of nirogacestat for the treatment of adults with desmoid tumors – .
SpringWorks Therapeutics, Inc : SpringWorks Therapeutics Announces European Medicines Agency Validation for Marketing Authorization Application of Nirogacestat for the Treatment of Adults with Desmoid Tumors finanznachrichten.de - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from finanznachrichten.de Daily Mail and Mail on Sunday newspapers.
Application based on Phase 3 DeFi trial in which nirogacestat significantly improved progression-free survival and objective response rate compared to placebo, with rapid and sustained improvements in.
SpringWorks Therapeutics (SWTX) Granted EMA Validation of Marketing Authorization Application of Nirogacestat streetinsider.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from streetinsider.com Daily Mail and Mail on Sunday newspapers.